Refractory GERD risk factors
Refractory GERD is simply GERD that is resistant to standard treatments, so the symptoms and risk factors are the same for both conditions. Refractory GERD and GERD may be influenced by several lifestyle and dietary factors, but you should speak with your healthcare professional before making any lifestyle or diet changes. Some causes may include
Obesity
Being overweight or obese appears to be one of the leading GERD risk factors. There may be a relationship between an increase in a person’s body mass index (BMI) and GERD symptoms.2
Dietary habits
Consuming certain kinds of food and drink is a potential GERD risk factor. Some of these foods and drinks include alcohol, carbonated drinks, fatty foods, spicy foods, chocolate, citrus fruits and juices, and mint.2
Smoking
Surveys have shown that smokers have higher rates of reflux symptoms than nonsmokers.2
Metozolv ODT is an orally disintegrating tablet that treats refractory GERD and improves symptoms.1 Talk to your healthcare professional to learn more about Metozolv ODT.
Learn how Metozolv ODT treats refractory GERD
Learn more about Metozolv ODT
Is Metozolv ODT right for you?
References: 1. METOZOLV ODT [package insert]. Morrisville, NC: Salix Pharmaceuticals, Inc; 2009.
2. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med. 2006;166:965-971.
IMPORTANT SAFETY INFORMATION
Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive
dyskinesia increases with the duration of treatment and the total cumulative dose.
Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive
dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.
Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh
the risk of developing tardive dyskinesia.
METOZOLV™ ODT (metoclopramide HCl) is indicated as short-term therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD)
who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric
stasis) in adults. Therapy should not exceed 12 weeks in duration. METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage,
or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal
reactions. METOZOLV ODT should be used with caution in patients showing acute dystonic reactions, drug-induced Parkinsonism, or other extrapyramidal symptoms;
neuroleptic malignant syndrome; with a prior history of depression; hypertension; congestive heart failure and ventricular arrhythmia. Patients may experience
withdrawal symptoms after stopping the use of METOZOLV ODT.
In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.
Please see accompanying full Prescribing Information
for Metozolv ODT, including BOXED WARNING.